-+ 0.00%
-+ 0.00%
-+ 0.00%

ELEDON PHARMACEUTICALS PRESENTS PHASE 2 BESTOW TRIAL DATA SHOWING SUSTAINED IMPROVEMENTS IN QUALITY OF LIFE AND SYMPTOM BURDEN WITH TEGOPRUBART COMPARED TO TACROLIMUS AT AMERICAN SOCIETY OF NEPHROLOGY KIDNEY WEEK 2026 ANNUAL MEETING

Reuters·10/26/2026 11:00:03

Please log in to view news